|
CA2215905A1
(en)
|
1995-03-20 |
1996-09-26 |
Sumitomo Electric Industries, Ltd. |
Monoclonal antibody reacting specifically with fas ligand and process for producing the same
|
|
WO1996040041A2
(en)
*
|
1995-06-07 |
1996-12-19 |
Chiron Corporation |
Antibodies to fas antigen capable of inhibiting apoptosis
|
|
US6096312A
(en)
*
|
1995-06-30 |
2000-08-01 |
Mochida Pharmaceutical Co., Ltd. |
Agent for suppressing a reduction of CD4+ lymphocytes
|
|
JPH09124509A
(ja)
*
|
1995-10-27 |
1997-05-13 |
Sumitomo Electric Ind Ltd |
肝炎治療剤
|
|
DE19544333C2
(de)
*
|
1995-11-28 |
1998-12-10 |
Deutsches Krebsforsch |
Verfahren zur Beurteilung der Aktivität von Arzneistoffen
|
|
AU2814897A
(en)
*
|
1996-04-25 |
1997-11-12 |
T Cell Sciences, Inc. |
Method of isolating regulators of t cell activation
|
|
GB9703276D0
(en)
*
|
1997-02-17 |
1997-04-09 |
Screaton Gavin R |
Materials and methods relating to the protection of useful immune cells
|
|
CA2308017A1
(en)
*
|
1997-10-30 |
1999-05-14 |
Erik S. Falck-Pedersen |
A method of inhibiting an immune response to a recombinant vector
|
|
EP1447093A1
(en)
|
2003-02-14 |
2004-08-18 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
|
|
PT1606318E
(pt)
|
2003-03-26 |
2009-11-10 |
Deutsches Krebsforsch |
Proteínas de fusão de fc melhoradas
|
|
SI2428252T1
(sl)
|
2006-12-28 |
2015-01-30 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Nevtralizacija invazije aktivnostnih blokov cd95 v celicah glioblastoma in vivo
|
|
WO2010003766A2
(en)
|
2008-06-17 |
2010-01-14 |
Apogenix Gmbh |
Multimeric tnf receptors
|
|
CN102497886B
(zh)
*
|
2009-07-21 |
2016-01-20 |
玛丽皇后与斯特菲尔德学院 |
用于细胞内药物递送的Fas(Apo-1，CD95)靶向平台
|
|
CN104640568B
(zh)
|
2012-07-18 |
2016-10-19 |
阿珀吉尼科斯股份公司 |
用于治疗mds的cd95信号传导途径的抑制剂
|
|
EP3076179A1
(en)
|
2015-03-30 |
2016-10-05 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Diagnosis and treatment of low grade gliomas
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
CA3049165A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
MX2019007963A
(es)
|
2017-01-06 |
2019-10-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
|
|
KR20200003913A
(ko)
|
2017-05-10 |
2020-01-10 |
이오반스 바이오테라퓨틱스, 인크. |
액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
US20210369775A1
(en)
|
2017-12-15 |
2021-12-02 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
CA3090795A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
WO2020180733A1
(en)
|
2019-03-01 |
2020-09-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
US20220177841A1
(en)
|
2019-03-29 |
2022-06-09 |
Myst Therapeutics Llc |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
US20230032934A1
(en)
|
2019-11-27 |
2023-02-02 |
Myst Therapeutics, Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
EP4512828A3
(en)
|
2020-02-27 |
2025-05-14 |
Turnstone Biologics Corp. |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2026044087A1
(en)
|
2024-08-21 |
2026-02-26 |
Shape Therapeutics Inc. |
Increased cellular stability for aav production
|
|
WO2026073032A1
(en)
|
2024-09-27 |
2026-04-02 |
Shape Therapeutics Inc. |
Constructs for improved aav production
|